Argos Therapeutics to Present at the Annual Sachs Immuno-Oncology: BD&L and Investment Forum

Argos Therapeutics Inc. ARGS ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced that Mr. Jeffrey D. Abbey, the company's president and chief executive officer will present at the Annual Sachs Immuno-Oncology: BD&L and Investment Forum held today at the Hyatt Chicago Magnificent Mile. Mr. Abbey will participate in a panel discussion titled, "Immunotherapeutics: ADCs and Combination Therapies – Science," beginning at 9:50am CDT. He will also present an overview of Argos during Track D at 2:30pm CDT. The Annual Sachs Immuno-Oncology: BD&L and Investment Forum brings together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. For more information visit http://www.sachsforum.com/sio15/.